EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The role of complement factor I rare genetic variants in age related macular degeneration in Finland

Anneliza Andreadi, Thomas M Hallam iD, Vicky Brocklebank, Scott J Sharp, Patrick R Walsh, Tom Southerington, Marco Hautalahti, David H Steel, Andrew J Lotery, Claire L Harris iD, Kevin J Marchbank, David Kavanagh iD und 1 weitere

Human Molecular Genetics · 2025

DOI: 10.1093/hmg/ddae165 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Molecular Genetics, 2025. Verfasst von Anneliza Andreadi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Framlington Place Newcastle upon Tyne, N…. Hauptthemen laut MEDLINE: Macular Degeneration, Complement Factor I. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council/Kidney Research UK Clinical Research Training Fellow, US National Institutes of Health, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. The alternative pathway (AP) of complement has been linked to the pathogenesis of AMD. In particular, rare variants (RVs) in the complement factor I (CFI) gene encoding the Factor I (FI) protein confer increased AMD risk. The prevalence of CFI RVs are well characterised in European AMD, however little is known about other populations. The Finnish population underwent genetic restriction events which have skewed allele frequencies in unexpected ways. A series of novel or enriched CFI RVs were identified in individuals with dry AMD from the Finnish Biobank Cooperative (FINBB), but the relationship between these genotypes and contribution to disease was unclear. Understanding how RVs impact the ability of FI to regulate the complement system is important to inform mechanistic understanding for how different genotypes contribute to disease development. To explore this a series of in vitro assays were used to functionally characterise the protein products of 3 CFI RVs enriched in FINBB dry AMD, where no prior data were available. The G547R variant resulted in almost complete loss of both classical pathway and AP regulatory potential. The c.982 g>a variant encoding G328R FI perturbed an exon splice enhancer site which resulted in exon skipping and a premature stop codon in vitro and low levels of FI in vivo. Despite detailed analysis no defect in levels or function was demonstrated in T107A. Functional characterization of all Finnish CFI RVs in the cohort allowed us to demonstrate that in Finnish dry AMD, collectively the type 1 CFI RVs (associated with FI haploinsufficiency) were significantly enriched with odds ratio (ORs) of 72.6 (95% confidence interval; CI 16.92 to 382.1). Meanwhile, type 2 CFI RVs (associated with FI dysfunction) collectively conferred a significant OR of 4.97 (95% CI 1.522 to 15.74), and non-impaired or normal CFI RV collectively conferred an of OR 3.19 (95% CI 2.410 to 4.191) although this was driven primarily by G261D. Overall, this study for the first time determined the ORs and functional effect for all CFI RVs within a Geographic Atrophy (GA) cohort, enabling calculations of combined risk scores that underline the risk conferred by type 1 and 2 CFI RVs in GA/AMD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macular DegenerationComplement Factor IHumansFinlandFemaleGenetic Predisposition to DiseaseMaleAgedGene FrequencyPolymorphism, Single NucleotideGenetic VariationGenotypeMiddle AgedComplement Pathway, Alternative

Stichwörter der Autor:innen

FINBBFinlandaHUSage related macular degenerationcomplementfactor Irare genetic variants

Substanzen

Complement Factor ICFI protein, human

Autor:innen und Institutionen

  • Complement Therapeutics Research Group, Translational and Clinical Research Institute, Newcastle University, Framlington Place Newcastle upon Tyne, NE2 4HH, United Kingdom.
  • National Renal Complement Therapeutics Centre, Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, United Kingdom.
  • Gyroscope Therapeutics Limited, A Novartis Company, Rolling Stock Yard, 188 York Way, London, N7 9AS, United Kingdom.
  • Finnish Biobank Cooperative Regus, Yliopistonkatu 31, 20100 Turku, Finland.
  • University of Turku, Hospital District of Southwest Finland, Finnish Biobank Cooperative - FINBB, Turku, Finland.
  • Biosciences Institute, Newcastle University, International Centre for Life, Central Parkway, Newcastle upon Tyne, NE1 3BZ, United Kingdom.

ORCID-Profile: Thomas M Hallam, Claire L Harris, David Kavanagh, Amy V Jones

Förderung

  • Medical Research Council/Kidney Research UK Clinical Research Training Fellow
  • US National Institutes of Health
  • Medical Research Council
  • NEI NIH HHS
  • NIHR Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals NHS Foundation Trust
  • Wellcome Trust
  • Wellcome Trust: 4Ward North Academy

Zitieren

APA

Andreadi, A., Hallam, T. M., Brocklebank, V., Sharp, S. J., Walsh, P. R., Southerington, T., Hautalahti, M., Steel, D. H., Lotery, A. J., Harris, C. L., Marchbank, K. J., Kavanagh, D., & Jones, A. V. (2025). The role of complement factor I rare genetic variants in age related macular degeneration in Finland. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddae165

Vancouver

Andreadi A, Hallam TM, Brocklebank V, Sharp SJ, Walsh PR, Southerington T, et al. The role of complement factor I rare genetic variants in age related macular degeneration in Finland. Human Molecular Genetics. 2025. doi:10.1093/hmg/ddae165

BibTeX
@article{Andreadi2025,
  author = {Andreadi, Anneliza and Hallam, Thomas M and Brocklebank, Vicky and Sharp, Scott J and Walsh, Patrick R and Southerington, Tom and Hautalahti, Marco and Steel, David H and Lotery, Andrew J and Harris, Claire L and Marchbank, Kevin J and Kavanagh, David and Jones, Amy V},
  title = {The role of complement factor I rare genetic variants in age related macular degeneration in Finland},
  journal = {Human Molecular Genetics},
  year = {2025},
  doi = {10.1093/hmg/ddae165}
}
Kostenlos starten →